H.C. Wainwright analyst Vernon Bernardino reiterated a Buy rating on ENDRA Life Sciences (NDRA) today and set a price target of $6.00. The company’s shares closed last Tuesday at $0.83, close to its 52-week low of $0.60.
According to TipRanks.com, Bernardino is a 5-star analyst with an average return of 28.2% and a 35.8% success rate. Bernardino covers the Healthcare sector, focusing on stocks such as Aridis Pharmaceuticals, Achieve Life Sciences, and Miragen Therapeutics.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for ENDRA Life Sciences with a $6.00 average price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $2.25 and a one-year low of $0.60. Currently, ENDRA Life Sciences has an average volume of 141K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
ENDRA Life Sciences, Inc. develops medical imaging technology. It operates Thermo-Acoustic Enhanced UltraSound platform to enable clinicians to visualize human tissue composition, function and temperature. The company was founded on July 18, 2007 and is headquartered in Ann Arbor, MI.
